HKMPF (Hikma Pharmaceuticals) ROE % Adjusted to Book Value : 2.35% (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Hikma Pharmaceuticals ROE % Adjusted to Book Value?

Hikma Pharmaceuticals's ROE % for the quarter that ended in Dec. 2023 was 5.38%. Hikma Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2023 was 2.29. Hikma Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was 2.35%.

Hikma Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Hikma Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals ROE % Adjusted to Book Value Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

8.64

5.46

6.80

4.21

3.83

Hikma Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															5.40	8.13	0.71	5.20	2.35

Competitive Comparison of Hikma Pharmaceuticals's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hikma Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's ROE % Adjusted to Book Value falls into.

Hikma Pharmaceuticals ROE % Adjusted to Book Value Calculation

Hikma Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	8.77%	/	2.29
	=	3.83%

Hikma Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	5.38%	/	2.29
	=	2.35%

Hikma Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (OTCPK:HKMPF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HIKl:UK HIK:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.